FDA Slaps Clinical Hold On Celyad's Phase 1 Colorectal Cancer Trial

The FDA has issued a clinical hold on Celyad Oncology SA's (NASDAQ:CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects.
As previously disclosed, the Company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.
Celyad Oncology is a clinical-stage biotechnology company focused on discovering and developing chimeric antigen receptor T cell (CAR T) therapies for cancer.
The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for hematological malignancies and solid tumors.
Price Action: CYAD shares closed 15.4% lower at $2.26 on Tuesday.

To add Benzinga News as your preferred source on Google, click here.